Japan Home versus Office blood pressure Measurement Evaluation for Assessment of the effects of mono and combination irbesartan therapy on microaLBuminuria

Phase 4

• Conditions: Hypertension

• Registration Number: JPRN-UMIN000004510
• Lead Sponsor: J-HOME-ALB study group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-11-08
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 260

Inclusion Criteria

Not provided

Exclusion Criteria

1) Hypersensitivity to components of compounds of irbesartan, amlodipine, efonidipine, or trichlormethiazide 2) Past history of major cardiac events or intervention (e.g., myocardial infarction, stroke) within 6 months prior to the start of the study. 3) Secondary hypertension other than renal hypertension 4) Casual or home blood pressure >= 180 / 110 mgHG 5) Patient with severe renal disease (serum creatinine >=2.0 mg/dL), acute renal failure, hyponatremia, or hypokalemia 6) Severe hepatic disease (ALT >= 100 IU/L) 7) Cardiac failure (above NYHA grade II) 8) Cancer or poor-prognosis diseases 9) Uncontrolled diabetes mellitus (HbA1c >= 8%) 10) Pregnancy or breast feeding, or a female expecting to conceive within the study 11) Patient ineligible to this study due to other medical reasons

Study & Design

• Study Type: Interventional
• Study Design: Not specified